Clinical trial
Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver…
NCT00238394 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00238394 |
|---|---|
| Title | Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer |
| Official title | A Phase II Study of AZD2171 in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer |
| Intervention type | Drug, Other |
| Interventions | cediranib maleate, laboratory biomarker analysis |
| Enrollment | 44 |
| Start date | Dec 1, 2005 |
| Primary completion | Mar 1, 2007 |
| First posted | Oct 13, 2005 |
| Last update posted | Jun 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: